Prospective study with the aim to investigate the biological relevance of fibrinolysis products and their use as prognostic and therapeutic biomarkers in SIRS and SEPSIS.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00000215

Enrollment

150

Registered

2010-08-23

Start date

2010-01-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A41.9

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Stay at ICU >=48h, positive consent, no active neoplasia (>10 years)

Exclusion criteria

Exclusion criteria: active Neoplasia, age <18 years, no consent

Design outcomes

Secondary

Measure	Time frame
The secondary endpoint consists in determining the concentrations of fibrin fragments in patient's blood samples and correlating the levels with the progression of disease from SIRS to SEPSIS. The secondary endpoint is reached at progression from SIRS to SEPSIS.	—

Primary

Measure	Time frame
The primary endpoint consists in determining the concentrations of fibrin fragments in patient's blood samples and correlating the levels with the overall survival. The primary endpoint is reached with transfer of the patient from intensive care unit.	—

Countries

Germany

Contacts

Public ContactPatrick Paulus

Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie Klinikum der J.W.-Goethe Universität

patrick.paulus@kgu.de+69 6301 87824

Outcome results